Published in:
01-12-2012 | Original Article
Low incidences of acute and chronic graft-versus-host disease after unrelated bone marrow transplantation with low-dose anti-T lymphocyte globulin
Authors:
Kazuo Hatanaka, Shigeo Fuji, Kazuhiro Ikegame, Ruri Kato, Atsushi Wake, Michihiro Hidaka, Toshiro Ito, Masami Inoue, Yoshihisa Nagatoshi, Akiyoshi Takami, Naokuni Uike, Hisashi Sakamaki, Hiromasa Yabe, Yasuo Morishima, Ritsuro Suzuki, Yoshiko Atsuta, Takahiro Fukuda
Published in:
International Journal of Hematology
|
Issue 6/2012
Login to get access
Abstract
Anti-T lymphocyte globulin (ATG) is commonly used as prophylaxis for graft-versus-host disease (GVHD), especially in patients who are at high risk of GVHD. The appropriate dosage of ATG in Japan has not yet been assessed. We therefore conducted a nationwide survey of patients who received ATG-Fresenius as GVHD prophylaxis for unrelated bone marrow transplantation (uBMT). A total of 86 patients were identified (median age 31 years, range 1–68). The median total dose of ATG was 10 mg/kg. The cumulative incidence of neutrophil engraftment was 90 %. The probability of 2-year overall survival (OS) was 67 %. The cumulative incidence of 2-year non-relapse mortality was 25 %. The incidences of grade II–IV and grade III–IV acute GVHD were 20 and 8 %, respectively. The incidences of chronic and extensive chronic GVHD were 19 and 8 %, respectively. In adult patients, there was a reduction of acute GVHD with high-dose ATG (>10 mg/kg), which did not reach statistical significance. In conclusion, the addition of low-dose ATG to GVHD prophylaxis in Japanese patients who received uBMT resulted in decreased incidences of both acute and chronic GVHD without compromising OS. The effects of low-dose ATG should be assessed in a prospective clinical trial.